Journal of Chemical Information and Modeling

Peter Madrid, Head of Scientific Discovery at Synfini, Joins Other Expert Speakers to Lead a National Academies of Sciences Workshop on AI for Scientific Discovery 

Retrieved on: 
Wednesday, October 11, 2023
National academy, AI, Observational comedy, National Academies of Sciences, Engineering, and Medicine, Journal, Science, Drug discovery, Journal of Chemical Information and Modeling, Cheminformatics, Medical device, Engineering, Medicine

MENLO PARK, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Synfini, Inc. , a pioneer in agile chemistry whose advanced, automated molecular discovery platform is transforming drug discovery, today announced that Peter Madrid, Synfini’s Head of Scientific Discovery, will join other expert speakers to lead a workshop titled “AI for Scientific Discovery” , October 12.

Key Points: 
  • MENLO PARK, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Synfini, Inc. , a pioneer in agile chemistry whose advanced, automated molecular discovery platform is transforming drug discovery, today announced that Peter Madrid, Synfini’s Head of Scientific Discovery, will join other expert speakers to lead a workshop titled “AI for Scientific Discovery” , October 12.
  • Hosted by The National Academies of Sciences, Engineering, and Medicine, the workshop will explore the future of AI-driven physical experimentation and discuss the technology and opportunities that are on the horizon.
  • The goal for this meeting is to explore the future of AI in terms of its role as an autonomous researcher performing scientific discovery.
  • This includes where AI stands, where it needs to go, and which disciplines should have increased investment for use by AI scientists.

Latham BioPharm Group Announces Publication of Team Member's Paper in Leading Scientific Journal

Retrieved on: 
Wednesday, September 21, 2022
JCIM, Journal, Doctor of Philosophy, Risk and strategic consulting, Free energy perturbation, Organization, New product development, Cros, FEP, Deep learning, Journal of Chemical Information and Modeling, RA, Grade (consulting), Cheminformatics, LBG, Drug discovery, AlphaFold, Medical device, Pharmaceutical industry

BALTIMORE, Sept. 21, 2022 /PRNewswire/ -- Latham Biopharm Group (LBG), in collaboration with researchers from RA Capital Management and Nostrum Biodiscovery, recently published a paper in the Journal of Chemical Information and Modeling (JCIM).

Key Points: 
  • BALTIMORE, Sept. 21, 2022 /PRNewswire/ -- Latham Biopharm Group (LBG), in collaboration with researchers from RA Capital Management and Nostrum Biodiscovery, recently published a paper in the Journal of Chemical Information and Modeling (JCIM).
  • The paper, which is titled " Are Deep Learning Structural Models Sufficiently Accurate for Free-Energy Calculations?
  • Application of FEP+ to AlphaFold2-Predicted Structures ," was written by LBG team member Thijs Beuming , Ph.D., Principal Consultant, and several co-authors.
  • A peer-reviewed scientific journal, the Journal of Chemical Information and Modeling publishes papers reporting new methodology and/or important applications in the fields of chemical informatics and molecular modeling.It is regarded as the leading journal for computer-aided drug design.

Exscientia Business Update for Second Quarter and First Half 2022

Retrieved on: 
Wednesday, August 17, 2022
Software, Research, General Health, Pharmaceutical, Oncology, Medical Devices, Technology, Health Technology, Clinical Trials, Science, Biotechnology, Health, Multimedia, Precision medicine, Table, Drug discovery, Inflammation, Surface plasmon resonance, BID, UK Research and Innovation, Trust law, Technology, USD, Toxicity, IND, Achievement, MAD, Research, GBP, DevOps, Probability, BMS, British Empire Medal, GPCR, Wellcome Trust, SAD, ACS Medicinal Chemistry Letters, Company, International, CTA, Federal Reserve Bank, Innovation, Partnership, MBE, Economics, Â, Biology, BST, Cheminformatics, Most, Journal, ID, Immunity, Federal Reserve Bank of New York, Journal of Chemical Information and Modeling, Pharmacokinetics, Pharmaceutical industry, Cryptocurrency, Vaccine, Medical imaging, Medical device, Online gambling, Bayer, Sanofi

View the full release here: https://www.businesswire.com/news/home/20220817005681/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220817005681/en/
    Recent developments in the Companys pipeline, collaborations, and operations, as well as financial results for the second quarter and first half 2022, are summarised below.
  • In addition, Exscientia will host a conference call Thursday, August 18 at 1:30 p.m. BST / 8:30 a.m.
  • In the first half of 2022, we delivered on major new and existing collaborations, advanced our pipeline programmes, and marked the 10-year anniversary of Exscientias founding.
  • A replay will be available for 90 days under "Events and Presentations in the Investors and Media section of the Exscientia website .